Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Non-Current Liabilities: 2023

Historic Total Non-Current Liabilities for Contineum Therapeutics (CTNM) over the last 1 years, with Dec 2023 value amounting to $5.6 million.

  • Contineum Therapeutics' Total Non-Current Liabilities was N/A to $6.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $5.6 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Contineum Therapeutics reported Total Non-Current Liabilities of $5.6 million as of FY2023.
  • In the past 5 years, Contineum Therapeutics' Total Non-Current Liabilities ranged from a high of $5.6 million in FY2023 and a low of $5.6 million during FY2023.
  • In the last 1 years, Contineum Therapeutics' Total Non-Current Liabilities had a median value of $5.6 million in 2023 and averaged $5.6 million.